25 results on '"Xiang, Yu-Tao"'
Search Results
2. Antidepressant prescription pattern in the presence of medical co-morbidity: REAP-AD 2013 study
- Author
-
Grover, Sandeep, Avasthi, Ajit, Tripathi, Adarsh, Tanra, Andi J, Chee, Kok-Yoon, He, Yang-Lin, Chiu, Helen FK, Kuga, Hironori, Lee, Min-Soo, Chong, Mian-Yoon, Udormatn, Pichet, Kanba, Shigenobu, Yang, Shu-Yu, Si, Tian-Mei, Sim, Kang, Tan, Chay-Hoon, Shen, Winston W, Xiang, Yu-Tao, Sartorius, Norman, and Shinfuku, Naotaka
- Published
- 2015
3. Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region.
- Author
-
Tang, Chao Tian, Chua, Ee Cheong, Chew, Qian Hui, He, Yan‐Ling, Si, Tian‐Mei, Chiu, Helen F.‐K., Xiang, Yu‐Tao, Kato, Takahiro A., Kanba, Shigenobu, Shinfuku, Naotaka, Lee, Min‐Soo, Park, Seon‐Cheol, Park, Yong‐Chon, Chong, Mian‐Yoon, Lin, Shih‐Ku, Yang, Shu‐Yu, Tripathi, Adarsh, Avasthi, Ajit, Grover, Sandeep, and Kallivayalil, Roy A.
- Subjects
SOCIAL skills ,SCHIZOPHRENIA ,DRUG side effects ,PSYCHOSES ,SYMPTOMS ,TREMOR ,ORAL habits - Abstract
Introduction: Patterns of clinical use of long‐acting injectable (LAI) antipsychotic drugs in many countries, especially in Asia, for treatment of patients diagnosed with chronic psychotic disorders including schizophrenia are not well established. Methods: Within an extensive research consortium, we evaluated prescription rates for first‐ (FGA) and second‐generation antipsychotic (SGA) LAI drugs and their clinical correlates among 3557 subjects diagnosed with schizophrenia across 15 Asian countries and region. Results: Overall, an average of 17.9% (638/3557; range: 0.0%‐44.9%) of treated subjects were prescribed LAI antipsychotics. Those given LAI vs orally administered agents were significantly older, had multiple hospitalizations, received multiple antipsychotics more often, at 32.4% higher doses, were more likely to manifest disorganized behavior or aggression, had somewhat superior psychosocial functioning and less negative symptoms, but were more likely to be hospitalized, with higher BMI, and more tremor. Being prescribed an FGA vs SGA LAI agent was associated with male sex, aggression, disorganization, hospitalization, multiple antipsychotics, higher doses, with similar risks of adverse neurological or metabolic effects. Rates of use of LAI antipsychotic drugs to treat patients diagnosed with schizophrenia varied by more than 40‐fold among Asian countries and given to an average of 17.9% of treated schizophrenia patients. We identified the differences in the clinical profiles and treatment characteristics of patients who were receiving FGA‐LAI and SGA‐LAI medications. Discussion: These findings behoove clinicians to be mindful when evaluating patients' need to be on LAI antipsychotics amidst multifaceted considerations, especially downstream adverse events such as metabolic and extrapyramidal side effects. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Coprescription of mood stabilizers in schizophrenia, dosing, and clinical correlates: An international study.
- Author
-
Lim, Wai Kwong, Chew, Qian Hui, He, Yan‐Ling, Si, Tian‐Mei, Chiu, Fung‐Kum Helen, Xiang, Yu‐Tao, Kato, Takahiro A., Kanba, Shigenobu, Shinfuku, Naotaka, Lee, Min‐Soo, Park, Seon‐Cheol, Park, Yong‐Chon, Chong, Mian‐Yoon, Lin, Shih‐Ku, Yang, Shu‐Yu, Tripathi, Adarsh, Avasthi, Ajit, Grover, Sandeep, Kallivayalil, Roy Abraham, and Udomratn, Pichet
- Subjects
MOOD stabilizers ,ARIPIPRAZOLE ,SCHIZOPHRENIA ,BODY mass index ,PSYCHOSES ,AMISULPRIDE ,SYMPTOMS - Abstract
Objective: Studies examining coprescription and dosages of mood stabilizers (MSs) with antipsychotics for psychotic disorders are infrequent. Based on sparse extant data and clinical experience, we hypothesized that adjunctive MS use would be associated with certain demographic (e.g., younger age), clinical factors (e.g., longer illness duration), and characteristics of antipsychotic treatment (e.g., multiple or high antipsychotic doses). Methods: Within an Asian research consortium focusing on pharmaco‐epidemiological factors in schizophrenia, we evaluated rates of MS coprescription, including high doses (>1000 mg/day lithium‐equivalents) and clinical correlates. Results: Among 3557 subjects diagnosed with schizophrenia in 14 Asian countries, MSs were coprescribed with antipsychotics in 13.6% (n = 485) of the sample, with 10.9% (n = 53) on a high dose. Adjunctive MS treatment was associated (all p < 0.005) with demographic (female sex and younger age), setting (country and hospitalization), illness (longer duration, more hospitalizations, non‐remission of illness, behavioral disorganization, aggression, affective symptoms, and social–occupational dysfunction), and treatment‐related factors (higher antipsychotic dose, multiple antipsychotics, higher body mass index, and greater sedation). Patients given high doses of MSs had a less favorable illness course, more behavioral disorganization, poorer functioning, and higher antipsychotic doses. Conclusions: Schizophrenia patients receiving adjunctive MS treatment in Asian psychiatric centers are more severely ill and less responsive to simpler treatment regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Cannabis use correlates with aggressive behavior and long-acting injectable antipsychotic treatment in Asian patients with schizophrenia.
- Author
-
Park, Seon-Cheol, Oh, Hong Seok, Tripathi, Adarsh, Kallivayalil, Roy Abraham, Avasthi, Ajit, Grover, Sandeep, Tanra, Andi Jayalangkara, Kanba, Shigenobu, Kato, Takahiro A., Inada, Toshiya, Chee, Kok Yoon, Chong, Mian-Yoon, Lin, Shih-Ku, Sim, Kang, Xiang, Yu-Tao, Tan, Chay Hoon, Javed, Afzal, Sartorius, Norman, Shinfuku, Naotaka, and Park, Yong Chon
- Subjects
AGGRESSION (Psychology) ,MARIJUANA ,PEOPLE with schizophrenia ,THERAPEUTICS ,LOGISTIC regression analysis - Abstract
Background: Although cannabis use has been linked with schizophrenia in a dose–response pattern, to our knowledge, the relationship between cannabis and schizophrenia has rarely been reported in Asian population. Aim: We compared the clinical characteristics and psychotropic prescription patterns between cannabis users and non-users among Asian patients with schizophrenia. Moreover, we aimed to identify the independent correlates of cannabis use in these subjects. Methods: We performed the analysis of the data from the Research on Asian Psychotropic Prescription Patterns for Antipsychotics (REAP-AP), a collaborative consortium survey used to collate the prescription patterns for antipsychotic and other psychotropic medications in patients with schizophrenia in Asia. We included 132 schizophrenia patients in the group of lifetime cannabis use and 1756 in the group that had never used cannabis. A binary logistic model was fitted to detect the clinical correlates of lifetime cannabis use. Results: Adjusting for the effects of age, sex, geographical region, income group, duration of untreated psychosis, and Charlson comordity index level, a binary logistic regression model revealed that lifetime cannabis use was independently associated with aggressive behavior [adjusted odds ratio (aOR) = 1.582, 95% confidence interval (CI) = 1.006–2.490, p =.047] and with long-acting injectable antipsychotic treatment (aOR = 1.796, 95% CI = 1.444–2.820, p =.001). Conclusion: Our findings indicate a close link between lifetime cannabis use and aggressive behavior. The use of long-acting, injectable antipsychotics preferentially treats the aggressive behavior cannabis users among patients with schizophrenia in Asia, especially, the South or Southeast Asia. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
6. A comparison of clinical characteristics of older adults treated with antidepressants in general and psychiatric hospitals in Asia.
- Author
-
Wang, Yuan ‐ Yuan, Xiang, Yu ‐ Tao, Ungvari, Gabor S., Ng, Chee H., Chiu, Helen F.K., Yim, Larina C.L., Si, Tian ‐ Mei, Chee, Kok ‐ Yoon, Avasthi, Ajit, Grover, Sandeep, Chong, Mian ‐ Yoon, Sim, Kang, Kanba, Shigenobu, He, Yan ‐ Ling, Lee, Min ‐ Soo, Yang, Shu ‐ Yu, Udomratn, Pichet, Kallivayalil, Roy A., Tanra, Andi J., and Maramis, Margarita M.
- Subjects
- *
ANTIDEPRESSANTS , *DRUG prescribing , *HOSPITALS , *MENTAL illness , *PSYCHIATRIC hospitals , *PSYCHOTHERAPY patients , *SCHIZOPHRENIA , *SEROTONIN uptake inhibitors , *PHYSICIAN practice patterns , *LOGISTIC regression analysis , *SOCIOECONOMIC factors , *ANXIETY disorders , *MIDDLE age - Abstract
Aim This study compared the demographics, clinical characteristics, and antidepressant prescription patterns between Asian patients aged 50 years and older attending psychiatric hospitals and those attending general hospitals. Methods In total, 955 patients (604 in general hospitals, 351 in psychiatric hospitals) aged 50 years or older treated with antidepressants in 10 Asian countries and territories were examined. Patients' demographics, clinical features, and prescriptions of psychotropic drugs were recorded using a standardized protocol and data collection procedure. Results Binary logistic regression revealed that high income and diagnosis of schizophrenia were independently associated with psychiatric hospital treatment, whereas outpatient care, diagnosis of anxiety disorders, and multiple major medical conditions were independently associated with general hospital treatment. In addition, tetracyclic and noradrenergic and specific serotonergic antidepressants were more likely to be prescribed in general hospitals. Conclusion Older adults treated with antidepressants showed different demographic and clinical features between general hospitals and psychiatric hospitals in Asia. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. Country variations in depressive symptoms profile in Asian countries: Findings of the Research on Asia Psychotropic Prescription ( REAP) studies.
- Author
-
Chee, Kok‐Yoon, Tripathi, Adarsh, Avasthi, Ajit, Chong, Mian‐Yoon, Xiang, Yu‐Tao, Sim, Kang, Si, Tian‐Mei, Kanba, Shigenobu, He, Yan‐Ling, Lee, Min‐Soo, Fung‐Kum Chiu, Helen, Yang, Shu‐Yu, Kuga, Hironori, Udormatn, Pichet, Kallivayalil, Roy A., Tanra, Andi J., Maramis, Margarita, Grover, Sandeep, Chin, Loi‐Fei, and Dahlan, Rahima
- Subjects
PUBLIC health ,PSYCHIATRIC drugs ,DRUG prescribing ,COGNITION - Abstract
Introduction This study was to assess differences in the symptom profile of depressive illness across various countries/territories in Asia. The study was a part of the Research on Asia Psychotropic Prescription project. The participating countries/territories include China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, Singapore, Taiwan, and Thailand. Methods The pattern of depressive symptoms in 1,400 subjects with depressive disorder from 42 psychiatric centers in 10 Asian countries/territories was assessed. We collected information on socio-demographic and clinical characteristics with a standardized protocol and data collection procedure. Results The most common presentations of depressive symptoms were persistent sadness, loss of interest, and insomnia. Similar findings were found regardless of the region, country, or its income level. Patients with depressive disorder from high-income countries presented significantly more with vegetative symptom cluster ( P < 0.05), while those from the upper middle-income countries had significantly more with both mood ( P < 0.001) and cognitive symptom clusters ( P < 0.01). In lower middle-income countries, patients with depressive symptoms had significantly less mood symptom cluster ( P < 0.001) but significantly more cognitive symptom cluster ( P < 0.05). Discussion This study demonstrates that in Asia, despite variations in the initial symptom reported by the patients, across different countries/territories, core depressive symptoms remain the same. Variations have been found in presentation of depressive symptoms with regards to the level of income of countries. Physical or vegetative symptoms were reported more by centers in higher income countries, while depressive cognition and suicidal thoughts/acts were more frequently reported from lower income countries. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. Use of electroconvulsive therapy for Asian patients with schizophrenia (2001-2009): Trends and correlates.
- Author
-
Xiang, Yu ‐ Tao, Ungvari, Gabor S., Correll, Christoph U., Chiu, Helen F. K., Lai, Kelly Y. C., Wang, Chuan ‐ Yue, Si, Tian ‐ Mei, Lee, Edwin H. M., He, Yan ‐ Ling, Yang, Shu ‐ Yu, Chong, Mian ‐ Yoon, Kua, Ee ‐ Heok, Fujii, Senta, Sim, Kang, Yong, Michael K. H., Trivedi, Jitendra K., Chung, Eun ‐ Kee, Udomratn, Pichet, Chee, Kok ‐ Yoon, and Sartorius, Norman
- Subjects
- *
ELECTROCONVULSIVE therapy , *SCHIZOPHRENIA treatment , *PEOPLE with schizophrenia , *ASIANS , *PSYCHIATRIC drugs , *CLINICAL trials , *PUBLIC health , *MEDICAL care , *DISEASES - Abstract
Aims Little is known about electroconvulsive therapy ( ECT) use in Asian inpatients with schizophrenia. This study examined trends of ECT use for schizophrenia patients in Asia between 2001 and 2009 and its independent demographic and clinical correlates. Methods Data on 6761 hospitalized schizophrenia patients (2001 = 2399, 2004 = 2136, and 2009 = 2226) in nine Asian countries and territories were collected by either chart review or interviews during a 1-month period. Patients' sociodemographic and clinical characteristics, prescriptions of psychotropic drugs and ECT use were recorded using a standardized protocol and data-collection procedure. Results The frequency of ECT was 3.3% in the whole sample; rising from 1.8% in 2001 to 3.3% in 2004 and 4.9% in 2009 ( P < 0.0001). However, this increased trend was driven solely by increased ECT use in China ( P < 0.0001), and the inclusion of India in the 2009 survey. There were wide inter-country variations: 2001, 0% ( Hong Kong, Korea) to 5.9% ( China); 2004, 0% ( Singapore) to 11.1% ( China); 2009, 0% ( Hong Kong) to 13.8% ( India) and 15.2% ( China). Multiple logistic regression analysis of the whole sample revealed that patients receiving ECT were less likely in the 35-64-year age group, had shorter length of current hospitalization and fewer negative symptoms, and were more likely to receive second-generation antipsychotic medications compared to those who were not treated with ECT (R2 = 0.264, P < 0.001). Conclusions ECT use for schizophrenia has increased over the past decade in China, being low/relatively stable in other Asian countries/regions. Reasons for substantial variations in ECT frequency in Asia require further study. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. Common use of anticholinergic medications in older patients with schizophrenia: findings of the Research on Asian Psychotropic Prescription Pattern (REAP) study, 2001-2009.
- Author
-
Xiang, Yu‐Tao, Dickerson, Faith, Kreyenbuhl, Julie, Ungvari, Gabor S., Wang, Chuan‐Yue, Si, Tian‐Mei, Lee, Edwin H. M., Chiu, Helen F. K., Lai, Kelly Y. C., He, Yan‐Ling, Yang, Shu‐Yu, Chong, Mian‐Yoon, Tan, Chay‐Hoon, Kua, Ee‐Heok, Fujii, Senta, Sim, Kang, Yong, Michael K. H., Trivedi, Jitendra K., Chung, Eun‐Kee, and Udomratn, Pichet
- Subjects
- *
PARASYMPATHOLYTIC agents , *SCHIZOPHRENIA in old age , *PSYCHIATRIC drugs , *THERAPEUTICS - Abstract
Objective This study surveyed the use of anticholinergic medications (ACMs) in older Asian patients with schizophrenia and examined its demographic and clinical correlates. Method A total of 1452 hospitalized patients with schizophrenia aged 55 years or older in nine Asian countries and territories were surveyed between 2001 and 2009. The cross-sectional data of patients' socio-demographic and clinical characteristics and the prescriptions of antipsychotic drugs and ACM were recorded using a standardized protocol and data collection procedure. Results The frequency of ACM prescription was 64.6% in the pooled sample, with 72.4%, 61.9%, and 59.5% in 2001, 2004, and 2009, respectively. Multiple logistic regression analysis of the whole sample revealed that patients on ACM had a higher dose of antipsychotic medications, and were more likely to have extrapyramidal side effects and receive first-generation antipsychotic medications. Conclusions Anticholinergic medications were frequently used in older Asian patients with schizophrenia. Considering the potential side effects of ACM, the rationale for their widespread use in this patient population should be revisited. Copyright © 2012 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. Use of first- and second-generation antipsychotic medications in older patients with schizophrenia in Asia (2001–2009).
- Author
-
Xiang, Yu-Tao, Kreyenbuhl, Julie, Dickerson, Faith B, Ungvari, Gabor S, Wang, Chuan-Yue, Si, Tian-Mei, Lee, Edwin H, He, Yan-Ling, Chiu, Helen F, Yang, Shu-Yu, Chong, Mian-Yoon, Tan, Chay-Hoon, Kua, Ee-Heok, Fujii, Senta, Sim, Kang, Yong, Michael K, Trivedi, Jitendra K, Chung, Eun-Kee, Udomratn, Pichet, and Chee, Kok-Yoon
- Subjects
- *
ANTIPSYCHOTIC agents , *DRUG prescribing , *RESEARCH funding , *RISPERIDONE , *OLANZAPINE , *PHYSICIAN practice patterns , *CROSS-sectional method , *ARIPIPRAZOLE , *QUETIAPINE , *DESCRIPTIVE statistics ,DRUG therapy for schizophrenia - Abstract
The article reports a study which examined the prescribing patterns of first- (FGAs) and second-generation antipsychotic (SGAs) medications administered to older Asian patients with schizophrenia. The results revealed that the SGA risperidone was the most commonly used antipsychotic in these patients followed by haloperidol, and chlorpromazine. Continuing education addressing the rational use of antipsychotics in this population is clearly needed because of reduced tolerability of older people.
- Published
- 2012
- Full Text
- View/download PDF
11. Adjunctive benzodiazepine treatment of hospitalized schizophrenia patients in Asia from 2001 to 2008.
- Author
-
Tor, Phern-Chern, Ng, Tze Pin, Yong, Kian-Hui, Sim, Kang, Xiang, Yu-Tao, Wang, Chuan-Yue, Lee, Edwin Ho Ming, Fujii, Senta, Yang, Shu-yu, Chong, Mian-Yoon, Ungvari, Gabor S., Si, Tianmei, He, Yan Ling, Chung, Eun Kee, Chee, Kok-Yoon, Trivedi, Jintendra, Udomratn, Pichet, Shinfuku, Naotaka, Kua, Ee Heok, and Tan, Chay Hoon
- Subjects
BENZODIAZEPINES ,SCHIZOPHRENIA treatment ,SIDE effects of antipsychotic drugs ,PEOPLE with schizophrenia ,CROSS-sectional method ,LOGISTIC regression analysis ,MULTIVARIATE analysis ,ASIANS ,DISEASES - Abstract
Benzodiazepines are commonly prescribed to patients with schizophrenia in many countries, but as little is known about such treatment in Asia, we evaluated their adjunctive use for 6761 in-patients diagnosed with schizophrenia in nine Asian countries using a cross-sectional study design in 2001, 2004 and 2008. Multivariate logistic regression and multivariate linear regression analyses were performed to assess predictors of benzodiazepine use and dose, respectively. Overall, 54% of the patients received adjunctive benzodiazepines at an average daily dose equivalent to 30.3 mg diazepam, with minor changes over the years sampled. Benzodiazepine use was highest in Taiwan and Japan, lowest in Thailand and China, and was associated with fewer years ill, presence of delusions (OR 1.24), hallucinations (OR 1.22), disorganized speech (OR 1.17), social or occupational dysfunction (OR 1.16), and use of mood stabilizers (OR 3.15), antiparkinsonian (OR 1.79) or antidepressant drugs (OR 1.33), and lower doses of antipsychotics (all p=0.016 to <0.001). Benzodiazepine doses were highest in Taiwan and China, lowest in Korea and Singapore; higher doses were associated with being young, male, physically aggressive, receiving mood stabilizers, and having electroconvulsive treatment (all p=0.019 to <0.001). Benzodiazepine use was associated with neurological and systemic adverse effects. In conclusion, benzodiazepine use was common in Asian patients with schizophrenia. Predictors of benzodiazepine use and dose differed in this population. Critical clinical guidelines should be developed specifically for Asian countries to address sound practices in regard to use of benzodiazepines for psychotic disorders. [ABSTRACT FROM PUBLISHER]
- Published
- 2011
- Full Text
- View/download PDF
12. The low frequency of reported sexual dysfunction in Asian patients with schizophrenia (2001-2009): low occurrence or ignored side effect?
- Author
-
Xiang, Yu-Tao, Wang, Chuan-Yue, Si, Tian-Mei, Lee, Edwin H. M., He, Yan-Ling, Ungvari, Gabor S., Chiu, Helen F. K., Yang, Shu-Yu, Chong, Mian-Yoon, Tan, Chay-Hoon, Kua, Ee-Heok, Fujii, Senta, Sim, Kang, Yong, Michael K. H., Trivedi, Jitendra K., Chung, Eun-Kee, Udomratn, Pichet, Chee, Kok-Yoon, Sartorius, Norman, and Shinfuku, Naotaka
- Subjects
- *
SEXUAL dysfunction , *SCHIZOPHRENIA , *PHARMACODYNAMICS , *SOCIODEMOGRAPHIC factors , *ANTIPSYCHOTIC agents - Abstract
Objective The purpose of the study was to evaluate the frequency of reported sexual dysfunction (SD) in schizophrenia and its associations with sociodemographic and clinical variables in selected Asian countries. Methods A total of 5877 schizophrenia patients in nine Asian countries and territories were examined between 2001 and 2009. The patients' sociodemographic and clinical characteristics, prescription of psychotropic drugs, and drug-induced side effects were recorded using a standardized protocol and data collection. SD was evaluated as 'present' or 'absent' according to the clinical judgment of experienced psychiatrists. Results The frequency of reported SD in the whole sample in women and men was 3.0%, 0.8%, and 4.6%, respectively, with variations across study sites. In the multivariate analyses, male sex, more second-generation antipsychotics, benzodiazepines, and antidepressants were independently associated with higher likelihood of reported SD, whereas negative symptoms had an inverse association with reported SD. Conclusions The results of this study indicate that SD was seldom recorded as a side effect by Asian psychiatrists while treating patients with schizophrenia. It is unclear whether the low prevalence of reported SD compared with Western data is real or whether the results are being insufficiently recognized. Copyright © 2011 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
13. Worldwide prevalence of falls in older adults with psychiatric disorders: A meta-analysis of observational studies.
- Author
-
Rao, Wen-Wang, Zeng, Liang-Nan, Zhang, Ji-Wen, Zong, Qian-Qian, An, Feng-Rong, Ng, Chee H., Ungvari, Gabor S., Yang, Fang-Yu, Zhang, Juan, Peng, Kelly Z., and Xiang, Yu-Tao
- Subjects
- *
OLDER people , *MENTAL illness , *META-analysis , *SCIENTIFIC observation , *SCIENCE databases - Abstract
Highlights • Falls are common in older adults with psychiatric disorders, but the findings across studies have been mixed. • The results suggest that prevalence of falls in older adults with psychiatric disorders vary across region, being highest in included countries in Europe and lowest in Asia. • Preventive measures of falls should be developed and implemented in psychiatric settings to reduce the risk of falls in this population. Abstract Falls are common in older adults with psychiatric disorders, but the epidemiological findings have been inconsistent. This meta-analysis examined the prevalence of falls in older psychiatric patients and its moderating factors. PubMed, EMBASE, Web of Science and PsycINFO databases were independently searched by three investigators from their inception date to Nov 31, 2017. The random effects meta-analysis was used to synthesize the prevalence of falls, while meta-regression and subgroup analyses were conducted to explore the moderating factors. Sixteen of the 2061 potentially relevant papers met the entry criteria for the meta-analysis. The pooled lifetime prevalence of falls was 17.25% (95% confidence interval: 13.14%–21.35%). Neither univariate and nor multivariate meta-regression analyses revealed any moderating effects of the study region, duration, sample size, and quality on the prevalence of falls (P values > 0.05). Falls in older adults with psychiatric disorders are common. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Suicidality is most centrally situated within network of depression symptom criteria in unipolar depression patients with mood stabilizer in Asia.
- Author
-
Yoon JW, Kim E, Jeong N, Kang M, Kim HS, Lee S, Yoon HJ, Kim SG, Na E, Yang H, Park JH, Yang SY, Lin SK, Zhu X, Xiang YT, Sim K, Tan CH, Grover S, Avasthi A, Kallivayalil RA, Maramis MM, Chee KY, Pariwatcharakul P, Oo T, Kato TA, Javed A, Chong MY, Sartorius N, Shinfuku N, Park J, and Park SC
- Subjects
- Humans, Adult, Male, Female, Middle Aged, Asia, Depressive Disorder, Treatment-Resistant drug therapy, Depressive Disorder, Treatment-Resistant diagnosis, Suicide, Attempted statistics & numerical data, Antimanic Agents therapeutic use, Antidepressive Agents therapeutic use, Depressive Disorder, Major drug therapy, Depressive Disorder, Major diagnosis, Depressive Disorder, Major epidemiology, Young Adult, Suicidal Ideation
- Abstract
Lithium and mood stabilizers are considered effective augmentation agents of antidepressants for treatment-resistant depression. Thus, this study aimed to estimate the network structure of depression symptom criteria among unipolar depression patients with mood stabilizers, using data from the Research on Asian Psychotropic Prescription Patterns for mood stabilizers (REAP-MS). We estimated a network of the 9 depression symptom criteria among 411 unipolar depression patients in Asia. Each of the depression symptom criteria was considered to be a dichotomous categorical variable. Suicidality (suicidal ideation or attempt) was the most centrally situated within the network of depression symptoms, followed by depressed mood, loss of energy, anhedonia and weight loss or gain. Contrastingly, concentration problem was the least interconnected. The depression symptom criteria were organized into 4 clusters by the community detection method. The findings suggest that suicidality may be one of the significant therapeutic target symptoms in unipolar depression patients with mood stabilizers., Competing Interests: Declaration of Competing Interest Seon-Cheol Park, an editorial board member of the Asian Journal of Psychiatry, was not involved in the evaluation of or decision to publish this article., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
15. Relationship Between Body Mass Index and Extrapyramidal Symptoms in Asian Patients with Schizophrenia: The Research on Asian Psychotropic Prescription Patterns for Antipsychotics (REAP-AP).
- Author
-
Park SC, Tripathi A, Avasthi A, Grover S, Tanra AJ, Kato TA, Inada T, Chee KY, Chong MY, Yang SY, Lin SK, Sim K, Xiang YT, Javed A, Sartorius N, Shinfuku N, and Park YC
- Subjects
- Asia, Humans, Overweight, Thinness, Antipsychotic Agents adverse effects, Antipsychotic Agents therapeutic use, Body Mass Index, Schizophrenia drug therapy
- Abstract
Background: Although an inverse relationship between body mass index (BMI) and Parkinson disease (PD) has been repeatedly reported, to our knowledge, the relationship between BMI and antipsychotic-induced extrapyramidal symptoms (EPS) has rarely been studied in patients with schizophrenia. Our study aimed to evaluate the relationship between BMI and EPS in patients with schizophrenia., Subjects and Methods: Using data from the Research on Asian Psychotropic Prescription Patterns for Antipsychotics (REAP-AP) study, we compared the prevalence of EPS in 1448 schizophrenia patients stratified as underweight, normal range, overweight pre-obese, overweight obese I, overweight obese II, and overweight obese III according to the World Health Organization (WHO) classification system for body weight status, and with underweight, normal range, overweight at risk, overweight obese I, and overweight obese II according to the Asia-Pacific obesity classification., Results: In the first step of the WHO classification system for body weight status, adjusting for the potential effects of confounding factors, the multinomial logistic regression model revealed that underweight was significantly associated with greater rates of bradykinesia and muscle rigidity, and a lower rate of gait disturbance. In the second step of the Asia-Pacific obesity classification, adjusting for the potential effects of confounding factors, the multinomial logistic regression model revealed that underweight was significantly associated with a higher rate of muscle rigidity., Conclusion: Findings of the present study consistently revealed that underweight was associated with a greater rate of muscle rigidity in a stepwise pattern among Asian patients with schizophrenia. Although the mechanism underlying the inverse relationship between BMI and muscle rigidity cannot be sufficiently explained, it is speculated that low BMI may contribute to the development of muscle rigidity regardless of antipsychotic "typicality" and dose in patients with schizophrenia.
- Published
- 2020
- Full Text
- View/download PDF
16. Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: Findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) survey.
- Author
-
Dong M, Zeng LN, Zhang Q, Yang SY, Chen LY, Najoan E, Kallivayalil RA, Viboonma K, Jamaluddin R, Javed A, Hoa DTQ, Iida H, Sim K, Swe T, He YL, Park Y, Ahmed HU, De Alwis A, Chiu HFK, Sartorius N, Tan CH, Chong MY, Shinfuku N, Lin SK, Avasthi A, Grover S, Ng CH, Ungvari GS, and Xiang YT
- Subjects
- Adult, Antidepressive Agents therapeutic use, Asia, Benzodiazepines therapeutic use, Cholinergic Antagonists therapeutic use, Cross-Sectional Studies, Drug Prescriptions statistics & numerical data, Female, Health Surveys, Humans, Male, Antipsychotic Agents therapeutic use, Practice Patterns, Physicians' statistics & numerical data, Schizophrenia drug therapy
- Abstract
Objective: Regular surveys are important to monitor the use of psychotropic medications in clinical practice. This study examined the psychotropic prescription patterns in adult Asian schizophrenia patients based on the data of the Research on Asian Psychotropic Prescription (REAP) 2016 survey., Methods: This cross-sectional survey across 15 Asian countries/territories collected socio-demographic and clinical data with standardized procedures between March and May 2016. The socio-demographic and clinical characteristics of the patients were recorded with a standardized questionnaire., Results: Altogether 3,537 adult patients with schizophrenia were consecutively screened and enrolled in the survey. The mean age was 38.66 ± 11.55 years and 59.7% of the sample were male. The mean dose of antipsychotics in chlorpromazine equivalents (CPZeq) was 424 ± 376 mg/day; 31.3% and 80.8% received first- and second- generation antipsychotics, respectively and 42.6% had antipsychotic polypharmacy, 11.7% had antidepressants, 13.7% had mood stabilizers, 27.8% had benzodiazepines, and 45.6% had anticholinergics., Conclusions: Psychotropic prescription patterns in Asian adult patients with schizophrenia varied across countries. Regular surveys on psychotropic medications for schizophrenia are important to monitor pharmacotherapy practice in Asia., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
17. Concurrent benzodiazepine use in older adults treated with antidepressants in Asia.
- Author
-
Zhong XM, Wang F, Zhang Q, Ungvari GS, Ng CH, Chiu HFK, Si TM, Sim K, Avasthi A, Grover S, Chong MY, Chee KY, Kanba S, Lee MS, Yang SY, Udomratn P, Kallivayalil RA, Tanra AJ, Maramis MM, Shen WW, Sartorius N, Mahendran R, Tan CH, Shinfuku N, and Xiang YT
- Subjects
- Aged, Asia, Databases, Factual, Female, Humans, Logistic Models, Male, Middle Aged, Antidepressive Agents therapeutic use, Benzodiazepines therapeutic use, Drug Prescriptions statistics & numerical data, Mental Disorders drug therapy, Polypharmacy
- Abstract
ABSTRACTBackground:Little is known about the combined use of benzodiazepines and antidepressants in older psychiatric patients. This study examined the prescription pattern of concurrent benzodiazepines in older adults treated with antidepressants in Asia, and explored its demographic and clinical correlates., Methods: The data of 955 older adults with any type of psychiatric disorders were extracted from the database of the Research on Asian Psychotropic Prescription Patterns for Antidepressants (REAP-AD) project. Demographic and clinical characteristics were recorded using a standardized protocol and data collection procedure. Both univariate and multiple logistic regression analyses were performed., Results: The proportion of benzodiazepine and antidepressant combination in this cohort was 44.3%. Multiple logistic regression analysis revealed that higher doses of antidepressants, younger age (<65 years), inpatients, public hospital, major comorbid medical conditions, antidepressant types, and country/territory were significantly associated with more frequent co-prescription of benzodiazepines and antidepressants., Conclusions: Nearly, half of the older adults treated with antidepressants in Asia are prescribed concurrent benzodiazepines. Given the potentially adverse effects of benzodiazepines, the rationale of benzodiazepines and antidepressants co-prescription needs to be revisited.
- Published
- 2019
- Full Text
- View/download PDF
18. Prevalence of overweight in schizophrenia patients in Asia: findings of the research on Asian psychotropic prescription patterns (REAP) study.
- Author
-
Wang F, Xiang YT, Ungvari GS, Ng CH, Chiu HF, Zheng W, Tan CH, and Shinfuku N
- Subjects
- Adult, Aged, Asia epidemiology, Female, Humans, Logistic Models, Male, Middle Aged, Practice Patterns, Physicians', Prevalence, Overweight epidemiology, Psychotropic Drugs therapeutic use, Schizophrenia drug therapy
- Abstract
Objective: This study examined the proportion of overweight in schizophrenia inpatients in selected Asian countries and territories and its independent demographic and clinical correlates., Method: Data on 1,534 hospitalized schizophrenia patients in 9 Asian countries and territories were collected by a review of medical files supplemented by a clinical interview during a 1-month period. Patients' sociodemographic and clinical characteristics, prescriptions of psychotropic drugs, and Body Mass Index (BMI) were recorded using a standardized protocol and data collection procedure. For analyzes, BMI ≥ 25 kg/m2 was defined as overweight., Results: The proportion of overweight was 35.8% (549/1,534) in the entire sample, with 39.7% (224/564) in females and 33.5% (325/970) in males (p = 0.01) and with wide inter-country variations. Multiple logistic regression analysis revealed that after controlling for study sites, overweight was independently associated with more frequent use of mood stabilizers (p < 0.001, odds ration (OR) = 1.4, 95% confidence interval (CI) = 1.1-1.8) and longer length of illness (p < 0.001, OR = 1.6, 95% CI = 1.2-2.1) but was less likely found in male patients (p = 0.003, OR = 0.7, 95% CI = 0.5-0.8)., Conclusions: The prevalence of overweight Asian schizophrenia patients is significantly lower than the reported figures among their Western counterparts. There is considerable variation in prevalence of overweight schizophrenia patients within Asian countries and territories.
- Published
- 2016
- Full Text
- View/download PDF
19. Implementation of psychiatric-focused lifestyle medicine programs in Asia.
- Author
-
Sarris J, Nishi D, Xiang YT, Su KP, Bannatyne A, Oliver G, Kua EH, and Ng CH
- Subjects
- Asia, Humans, Diet Therapy, Exercise Therapy, Life Style, Mental Disorders therapy, Mindfulness, Patient Education as Topic, Psychotherapy
- Abstract
Lifestyle-focused health programs are growing in interest throughout Western society, and a range of lifestyle factors are known to enhance both physical and mental health. However, it remains largely unknown as to whether this approach is salient for the Asian context. The major components of integrative lifestyle-focused health programs to enhance mental and physical health are considered to include the evidence-based adoption of physical activity and exercise, dietary modification, general psychoeducation, adequate relaxation/sleep and social interaction, use of mindfulness techniques, the reduction of substance use, attention of intersecting environmental factors, and the potential use of motivation and goal-setting techniques. This paper outlines an overview of the evidence underpinning these elements, and discusses potential barriers and challenges, and what logistical considerations may need to be addressed in the implementation of such programs within the context of Asian cultures., (© 2015 Wiley Publishing Asia Pty Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
20. Prevalence and prescription of antidepressants in depression with somatic comorbidity in Asia: the Research on East Asian Psychotropic Prescription Patterns study.
- Author
-
Chen C, Si TM, Xiang YT, Ungvari GS, Wang CY, He YL, Kua EH, Fujii S, Sim K, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Tan CH, and Shinfuku N
- Subjects
- Adult, Asia, Asian People, Female, Humans, Male, Middle Aged, Prevalence, Antidepressive Agents therapeutic use, Depression drug therapy, Depression epidemiology, Drug Prescriptions statistics & numerical data
- Abstract
Background: Depression is often comorbid with chronic somatic diseases. Few previous studies have investigated the prevalence of somatic diseases in depression or the prescription pattern of antidepressants in comorbidly depressed patients in Asia. This study aimed to investigate the prevalence of somatic comorbidity (SC) in depression and compared the prescriptions of antidepressants in depressed patients with and without SC., Methods: A total of 2320 patients treated with antidepressants in 8 Asian countries were examined, and a diagnosis was based on the International Classification of Disease, 10 th revision. We listed 17 common chronic somatic diseases. Patients' socio-demographic and clinical characteristics and psychotropic drug prescriptions were recorded using a standardized protocol and data collection procedure., Results: Of the patients examined, 1240 were diagnosed with depression and 30% of them (n = 375) had SC. The most common comorbid condition was diabetes (23.7%). The patients with SC were more likely to seek help at a general hospital (74.7% vs. 47.2%), and had a higher incidence of symptoms involving sadness, disturbed sleep, and poor appetite. Noradrenergic and specific serotonergic antidepressant was prescribed more for patients with SC than for those without SC (30.4% vs. 22.9%)., Conclusions: SC is common in depressed Asian patients. It is important to strengthen the recognition of depression, especially in general hospitals and when patients report some somatic discomfort. It is also a matter of urgency to establish evidence-based guidelines for the use of new antidepressants in depressed patients with SC.
- Published
- 2015
- Full Text
- View/download PDF
21. QTc prolongation in schizophrenia patients in Asia: clinical correlates and trends between 2004 and 2008/2009.
- Author
-
Xiang YT, Chiu HF, Ungvari GS, Correll CU, Lai KY, Wang CY, Si TM, Lee EH, He YL, Yang SY, Chong MY, Kua EH, Fujii S, Sim K, Yong MK, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Tan CH, and Shinfuku N
- Subjects
- Adult, Aged, Antipsychotic Agents adverse effects, Asia epidemiology, Electrocardiography, Female, Health Surveys, Hospitalization statistics & numerical data, Hospitalization trends, Humans, International Cooperation, Logistic Models, Long QT Syndrome chemically induced, Long QT Syndrome diagnosis, Male, Middle Aged, Retrospective Studies, Schizophrenia drug therapy, Long QT Syndrome epidemiology, Schizophrenia epidemiology
- Abstract
Objective: Little is known about the pattern of QT interval (QTc) prolongation in Asian patients with schizophrenia. This study examined trends of QTc prolongation in schizophrenia inpatients in six Asian countries and territories between 2004 and 2008/2009 and its independent demographic and clinical correlates., Method: Data on 3482 hospitalized schizophrenia patients (2004 = 1826 and 2008/2009 = 1656) in six Asian countries and territories were collected by either chart review or interviews during a 1-month period. Patients' sociodemographic and clinical characteristics, prescriptions of psychotropic drugs, and QTc interval were recorded using a standardized protocol and data collection procedure., Results: The frequency of QTc prolongation (>456 ms) was 2.4% in the whole sample, decreasing from 3.1% in 2004 to 1.6% in 2008/2009 (p = 0.004) with wide intercountry variations. However, this decreased trend was driven by decreased QTc prolongation detected in China and Hong Kong (both p-values < 0.05). Multiple logistic regression analysis of the whole sample revealed that patients having more likely to have an illness lasting longer than 5 years and received antipsychotics classified as list-1 drugs according to the Arizona Centre for Education and Research on Therapeutics. Compared with 2004, patients in 2008/2009 were less likely to have QTc prolongation. Thioridazine caused QTc prolongation most frequently (odds ratio (OR) 4.4; 95% confidence interval (CI) 1.2-15.2), followed by sulpiride (OR 2.4; 95% CI 1.3-4.5), clozapine (OR 2.4; 95% CI 1.4-4.2), and chlorpromazine (OR 1.9; 95% CI 1.07-3.5)., Conclusions: Frequency of QTc prolongation was low in Asian patients with schizophrenia. QTc prolongation in schizophrenia decreased in China and Hong Kong between 2004 and 2008/2009 but increased in Taiwan over the same period, remaining low in the other countries., (Copyright © 2015 John Wiley & Sons, Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
22. Use of clozapine in older Asian patients with schizophrenia between 2001 and 2009.
- Author
-
Xiang YT, Buchanan RW, Ungvari GS, Chiu HF, Lai KY, Li YH, Si TM, Wang CY, Lee EH, He YL, Yang SY, Chong MY, Kua EH, Fujii S, Sim K, Yong MK, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Tan CH, and Shinfuku N
- Subjects
- Adult, Aged, Asia epidemiology, Female, Health Surveys, Humans, Male, Middle Aged, Schizophrenia epidemiology, Time Factors, Young Adult, Antipsychotic Agents therapeutic use, Clozapine therapeutic use, Practice Patterns, Physicians', Schizophrenia drug therapy
- Abstract
Background: To date there has been no large-scale international study that examined the use of clozapine in older patients with schizophrenia. This study examined the use of clozapine and its demographic and clinical correlates in older patients with schizophrenia in East Asia during the period between 2001 and 2009., Method: Information on 1,157 hospitalized patients with schizophrenia aged 50 or older in five East Asian countries and territories (China, Hong Kong, Korea, Singapore and Taiwan) was extracted from the database of the Research on Asian Psychotropic Prescription Patterns (REAP) project. Socio-demographic and clinical characteristics and prescription of psychotropic medications were recorded., Results: Clozapine was prescribed for 20.6% of the pooled sample; 19.0% in 2001, 19.4% in 2004 and 22.9% in 2009. Multiple logistic regression analysis of the whole sample revealed that patients taking clozapine had a longer duration of illness, more negative symptoms and were less likely to receive first generation antipsychotic and anticholinergic drugs, but more likely to report weight gain compared to those not receiving clozapine. Compared to those in other sites, older patients in China were more likely to receive clozapine., Conclusions: The prescription of clozapine for older Asian schizophrenia inpatients has remained at a stable level during the past decade. The appropriateness of use of clozapine in China needs to be further explored.
- Published
- 2013
- Full Text
- View/download PDF
23. Adjunctive antidepressant prescriptions for hospitalized patients with schizophrenia in Asia (2001-2009).
- Author
-
Xiang YT, Ungvari GS, Wang CY, Si TM, Lee EH, Chiu HF, Lai KY, He YL, Yang SY, Chong MY, Tan CH, Kua EH, Fujii S, Sim K, Yong MK, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, and Shinfuku N
- Subjects
- Adult, Asia epidemiology, Chemotherapy, Adjuvant statistics & numerical data, Female, Hospitalization statistics & numerical data, Humans, Longitudinal Studies, Male, Practice Patterns, Physicians' statistics & numerical data, Schizophrenia epidemiology, Antidepressive Agents therapeutic use, Drug Prescriptions statistics & numerical data, Schizophrenia drug therapy
- Abstract
Introduction: Little is known about the prescription patterns of adjunctive antidepressants in Asian schizophrenia patients. This study aimed to examine trends in the use of antidepressants and their demographic and clinical correlates in the treatment of schizophrenia in Asia between 2001 and 2009., Methods: A total of 6,761 hospitalized schizophrenia patients in nine Asian countries and territories were examined: 2,399 in 2001, 2,136 in 2004 and 2,226 in 2009. Patients' socio-demographic and clinical characteristics and prescriptions of psychotropic drugs were recorded using a standardized protocol and data collection procedure., Results: The proportion of antidepressant prescription was 6.8% in the whole sample; 5.3% in 2001, 6.5% in 2004 and 8.7% in 2009. There were wide inter-country variations at each survey ranging from 0.9% in Hong Kong to 15.3% in Singapore in 2001; from 1.9% in Korea to 15.4% in Singapore in 2004; and from 2.7% in Japan to 22.0% in Singapore in 2009. Multiple logistic regression analysis of the whole sample revealed that patients on antidepressants were younger, more likely to receive benzodiazepines and have significant extrapyramidal side-effects and less likely to have significant positive symptoms., Discussion: Unlike findings in Western countries, adjunctive antidepressant prescription for schizophrenia was not common in Asia. The frequency of antidepressant prescription varied among countries and territories, suggesting that a host of clinical and socio-cultural factors played a role in determining antidepressant use in Asia., (Copyright © 2012 Wiley Publishing Asia Pty Ltd.)
- Published
- 2013
- Full Text
- View/download PDF
24. Adjunctive mood stabilizer treatment for hospitalized schizophrenia patients: Asia psychotropic prescription study (2001-2008).
- Author
-
Sim K, Yong KH, Chan YH, Tor PC, Xiang YT, Wang CY, Lee EH, Fujii S, Yang SY, Chong MY, Ungvari GS, Si T, He YL, Chung EK, Chee KY, Trivedi J, Udomratn P, Shinfuku N, Kua EH, Tan CH, Sartorius N, and Baldessarini RJ
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antimanic Agents administration & dosage, Antipsychotic Agents administration & dosage, Asia, Cross-Sectional Studies, Diagnostic and Statistical Manual of Mental Disorders, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Schizophrenia physiopathology, Young Adult, Antimanic Agents therapeutic use, Antipsychotic Agents therapeutic use, Practice Patterns, Physicians' trends, Schizophrenia drug therapy
- Abstract
Recent studies indicate relatively high international rates of adjunctive psychotropic medication, including mood stabilizers, for patients with schizophrenia. Since such treatments are little studied in Asia, we examined the frequency of mood-stabilizer use and its clinical correlates among hospitalized Asian patients diagnosed with schizophrenia in 2001-2008. We evaluated usage rates of mood stabilizers with antipsychotic drugs, and associated factors, for in-patients diagnosed with DSM-IV schizophrenia in 2001, 2004 and 2008 in nine Asian regions: China, Hong Kong, India, Korea, Japan, Malaysia, Taiwan, Thailand, and Singapore. Overall, mood stabilizers were given to 20.4% (n=1377/6761) of hospitalized schizophrenia patients, with increased usage over time. Mood-stabilizer use was significantly and independently associated in multivariate logistic modeling with: aggressive behaviour, disorganized speech, year sampled (2008 vs. earlier), multiple hospitalizations, less negative symptoms, younger age, with regional variation (Japan, Hong Kong, Singapore>Taiwan or China). Co-prescription of adjunctive mood stabilizers with antipsychotics for hospitalized Asian schizophrenia patients increased over the past decade, and was associated with specific clinical characteristics. This practice parallels findings in other countries and illustrates ongoing tension between evidence-based practice vs. individualized, empirical treatment of psychotic disorders.
- Published
- 2011
- Full Text
- View/download PDF
25. Sex differences in use of psychotropic drugs and drug-induced side effects in schizophrenia patients: findings of the Research on Asia Psychotropic Prescription (REAP) studies.
- Author
-
Xiang YT, Wang CY, Si TM, Lee EH, He YL, Ungvari GS, Chiu HF, Yang SY, Chong MY, Shinfuku N, Tan CH, Kua EH, Fujii S, Sim K, Yong KH, Trivedi JK, Chung EK, Udomratn P, Chee KY, and Sartorius N
- Subjects
- Adult, Age Factors, Antipsychotic Agents adverse effects, Asia, Drug Utilization statistics & numerical data, Female, Humans, Male, Middle Aged, Surveys and Questionnaires, Antipsychotic Agents therapeutic use, Schizophrenia drug therapy, Sex Characteristics
- Abstract
Objective: The aim of this study was to investigate the sex differences in prescribing patterns of psychotropic drugs and drug-induced side effects in schizophrenia patients in Asia using the data of the Research on Asian Psychotropic Prescription Pattern (REAP) surveys., Method: The prescription patterns of 6,441 schizophrenia inpatients in six Asian countries and regions were investigated during the 2001-2009 period. The patients' socio-demographic and clinical characteristics and their prescriptions for psychotropic drugs were recorded using a standardized protocol and data collection procedure., Results: Univariate analyses found the following factors to be significantly associated with the male sex: a younger age, higher doses of antipsychotics, less prominent delusions and hallucinations, more prominent negative symptoms, less likelihood of a prescription for second-generation antipsychotics (SGAs), greater use of antipsychotic polypharmacy, mood stabilizers and depot antipsychotics, more frequent tardive dyskinesia (TD), and less weight gain. In multivariate analyses, fewer prescriptions for SGAs, greater use of mood stabilizers, anticholinergics, antipsychotic polypharmacy and depot antipsychotics, extrapyramidal side effects (EPS) and TD, and less weight gain were independently associated with the male sex., Conclusions: Sex is one of the independent contributors to psychotropic prescription and side effects in Asian schizophrenia patients. Psychopharmacological treatment guidelines for schizophrenia should consider the sexes separately.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.